About
INTERCEPT-T2D develops a novel anti-inflammatory therapeutic approach and diagnostic biomarkers to identify and prevent complications in high-risk Type 2 Diabetes patients by targeting inflammatory-mediated disease progression.
Explore INTERCEPT-T2D's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.